Organisation paid for research Program year 2025 Source: CMS Open Payments

Chris Recknor MD PC

Neither a doctor nor a teaching hospital

Research payments

$71,551

27 payments

Through program year 2025, Chris Recknor MD PC is reported as receiving $71,551 in research payments, across 27 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $94 1
2024 Research $5,545 2
2023 Research $7,465 2
2022 Research $9,413 2
2021 Research $13,980 13
2020 Research $23,212 2
2019 Research $11,841 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $70,432 26 payments
  2. Amgen Inc. $1,119 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $32,314 5 payments
  2. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $17,499 5 payments
  3. A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly As Add-On Therapy to Metformin in Patients With Type 2 Diabetes $11,561 3 payments
  4. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $4,669 1 payment
  5. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized Double-Blind Placebo-Controlled Trial (Surmount-1) $2,796 1 payment
  6. Ph3 PMO Fracture Study ALN SupVert $1,119 1 payment
  7. Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-To-Severe Plaque Psoriasis $993 1 payment
  8. A Multicenter Randomized Double Blind Placebo Controlled Study Comparing the Efficacy and Safety of Ly2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis $223 1 payment
  9. A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3561774 $50 1 payment
  10. A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis $50 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record